Quinoline Derivatives for Anti-Cancer Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of substituted quinoline-type alkaloids with effective anti-cancer properties that also possess good solubility and acceptable cell toxicity for cancer treatment.
Innovation Solution
Development of specific quinoline derivatives with varied substituents in their ring moieties and side chains, synthesized through methods involving selenium dioxide, hydrogenation, and asymmetric synthesis, which demonstrate potent anti-tumor activities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If substituted quinoline-type alkaloids are developed for anti-cancer activity, then anti-tumor effectiveness is improved, but solubility and cell toxicity become problematic
Solution Approach 1:
The patent modifies molecular parameters of quinoline derivatives by introducing specific substituents at defined positions (R1-R8) to optimize the balance between anti-tumor activity and cell toxicity. The structural modifications include varying substituent types and positions to achieve desired pharmacological properties.
Solution Approach 2:
The invention creates composite molecular structures by combining quinoline core with various functional groups and substituents (hydroxyl, amino, carboxyl, etc.) to produce derivatives that exhibit enhanced anti-cancer activity while maintaining acceptable solubility and toxicity profiles.
2Reliability
If quinoline derivatives are synthesized with varied substituents to enhance anti-cancer activity, then anti-tumor effectiveness is improved, but synthesis complexity increases
Solution Approach 1:
The synthesis methodology is divided into discrete steps: starting material preparation, asymmetric hydrogenation with chiral ligands, and subsequent functional group transformations. This segmentation allows for systematic exploration of different substituents while maintaining a manageable synthesis framework.
Solution Approach 2:
The patent employs chiral ligands and catalysts as intermediaries in the asymmetric hydrogenation step to control stereochemistry. These intermediaries enable the formation of specific enantiomers with desired biological activity, simplifying the overall synthesis by focusing on key transformation steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The synthesized quinoline derivatives exhibit significant cytotoxic effects against various cancer cell lines, with some showing greater activity than standard anti-cancer agents like CDDP, and demonstrate in vivo anti-cancer effects by suppressing tumor growth without observable toxicity.
Implementation Method 1
The compound of formula (I) is prepared by the following steps: (a) oxidation of a compound of formula (II) with selenium dioxide to give a compound of formula (III)
Implementation Method 2
Asymmetric hydrogenation offers a new method for structural modification of this compound type to produce new chiral structural moiety and associated bioactivity. Zhou, Chan and others reported their effort in the asymmetric production of chiral tetrahydroquinoline with high enantioselectivities.
Data Source
AI summary
Quinoline derivatives showing anticancer activities against cancer cell lines of hepatocellular carcinoma (Hep3B), lung carcinoma (A549), esophageal squamous cell carcinoma (HKESC-1, HKESC-4 and KYSE150). The quinoline derivatives have a backbone structure of the following formulas: